Drug Reimbursement Recommendations
CADTH Common Drug Review (CDR)
Reviews drugs and makes reimbursement recommendations to Canada's federal, provincial, and territorial public drug plans, with the exception of Quebec, to guide their drug funding decisions.
CADTH pan-Canadian Oncology Drug Review (pCODR)
Reviews cancer drugs and makes reimbursement recommendations to Canada's provincial and territorial public drug plans, with the exception of Quebec, and to provincial cancer agencies to guide their cancer drug funding decisions.
Health Technology Management Program
Rapid Response Service
Provides rapid reviews of health technologies to support timely health care decision-making.
Health Technology Assessment Service
Delivers a comprehensive assessment of the clinical and/or economic evidence on health technologies; may include ethical, legal, and social implications.
Optimal Use Service
Delivers a CADTH Health Technology Assessment, with recommendations from an expert panel or committee.
Reviews current health care practices, processes, or protocols to enable a better understanding of the national or international landscape.
Reviews new and emerging health technologies that are likely to have a significant impact on the delivery of health care in Canada.
Other Programs and Services
Offers pharmaceutical companies advice on their early drug development plans from a health technology assessment perspective.